ArticleSurgery today2026
Impact of the albumin-C-reactive protein-tumor marker score on postoperative prognosis in very elderly patients with colorectal cancer.
Article in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe developed an albumin-C-reactive protein-tumor marker (ACTM) score and assessed its prognostic significance in elderly patients undergoing curative resection for colorectal cancer.
methodsWe retrospectively analyzed data from 232 patients > 80 years old who underwent surgery for Stage I–III colorectal cancer. The ACTM score was calculated by assigning 1 point each for the following factors: C-reactive protein > 0.5 mg/dL, albumin < 3.5 g/dL, and either carcinoembryonic antigen ≥ 5.0 ng/mL or carbohydrate antigen 19 − 9 ≥ 37 U/mL. We examined the association between ACTM score and survival outcomes.
resultsHigher ACTM scores were significantly associated with a worse relapse-free (P < 0.01) and overall survival (P < 0.01). In a multivariate analysis, an American Society of Anesthesiologists physical status ≥ 2 (P < 0.01), lymph node metastasis (P < 0.01), and ACTM score ≥ 2 (P < 0.01) were independent predictors of the 5-year relapse-free survival, whereas male sex (P < 0.01), neutrophil-to-lymphocyte ratio ≥ 3.5 (P < 0.01), and ACTM score ≥ 2 (P < 0.01) were independent predictors of the 5-year overall survival.
conclusionsThe ACTM score, which combines nutritional and inflammatory response indices with tumor markers, may predict the prognosis of very elderly patients with colorectal cancer.
Indexed as
Identifiers
41553397What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.